S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL. (23rd June 2022)

• Record Type: Journal Article
• Authors: Zinzani, P. L.; Mayer, J.; Auer, R.; Bijou, F.; de Oliveira, A. C.; Flowers, C. R.; Merli, M.; Bouabdallah, K.; Ganly, P. S.; Song, Y.; Zhang, H.; Johnson, R.; García-Sancho, A. M; Provencio, M.; Trněný, M.; Yuen, S.; Tilly, H.; Kingsley, E.; Tuyman, G.; Assouline, S. E.; Ivanova, E.; Kim, P.; Huang, J.; Delarue, R.; Trotman, J.
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 106
• Page End: 107
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000843712.33707.fe
• Languages: English
• ISSNs: 2572-9241